Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

A clinical practice guideline that stresses a multidisciplinary approach is intended to help clinicians manage obesity in ...

The pharmaceutical giant scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

A new guideline for treating obesity in children and adolescents says medication can be helpful, but that health providers ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

Obesity is on the rise. Among U.S. adults aged 20 or older, 4 in 10 met the criteria for obesity in the most recent National Health and Nutrition Examination Survey, up from roughly 3 in 10 two ...

A new guideline to help health care providers manage obesity in children and adolescents takes a patient-centered approach, ...

Across China, authorities are busting their humps trying to get people to shrink their waistlines. They’re promoting lite ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Johns Hopkins University-led research has found that obesity, particularly severe obesity, is strongly associated with the ...